Skip to main content

BTAI

Stock
Health Care
Biotechnology

Performance overview

BTAI Price
Price Chart

Forward-looking statistics

Beta
1.78
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Company info

SectorHealth Care
IndustryBiotechnology
Employees123
Market cap$53.1M

Fundamentals

Enterprise value$85.8M
Revenue$1.9M
Revenue per employee—
Profit margin5.43%
Debt to equity-1.17

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$11.12
Dividend per share—
Revenue per share$0.57
Avg trading volume (30 day)$848K
Avg trading volume (10 day)$793K
Put-call ratio—

Macro factor sensitivity

Growth+15.0
Credit-19.5
Liquidity-4.5
Inflation+13.2
Commodities+6.4
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-1.16
Price to sales6.31
P/E Ratio-1.16
Enterprise Value to Revenue46.34
Price to book-0.10

Upcoming events

Next earnings dayMay 12, 2025
Next dividend day—
Ex. dividend day—

News

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $2.72. This compares to loss of $13.92 per share a year ago.

Zacks Investment Research (May 12, 2025)
Why BioXcel Therapeutics Stock Is Surging Today

BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMIĀ (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in.

Benzinga (April 6, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free